HIMS Stock
4 articles on HIMS Stock, written by Shotlee and medically reviewed for clinical accuracy.
Hims & Hers Opens $149 Wegovy & Ozempic Waitlist via Novo Deal
Hims & Hers Health (NYSE: HIMS) is now offering a waitlist for affordable branded Wegovy and Ozempic at $149, thanks to a new Novo Nordisk deal. This expands access to these popular GLP-1 weight-loss drugs amid high demand. Meanwhile, HIMS stock shows short-term rebound potential in a downtrend—dive into the technicals and analyst views.
5 min read
Hims & Hers Shares Sink 16% as FDA Halts Wegovy Copycat Pill
Hims & Hers Health Inc. (HIMS) has halted sales of its copycat Wegovy weight loss pill just two days after launch, leading to a 16% plunge in shares amid FDA warnings and Novo Nordisk threats. This marks a regulatory pivot as GLP-1 shortages ease. Patients and investors should note the growing scrutiny on compounded versions of popular drugs like Wegovy.
5 min read
HIMS Shares Sink After FDA Vows Swift Action on Copycat GLP-1 Drugs
Hims & Hers Health's bold launch of a $49-per-month copycat GLP-1 pill to rival Wegovy's $149 price tag backfired spectacularly. FDA Commissioner Marty Makary vowed 'swift action' against such unapproved drugs, sending HIMS shares down 7.5% in premarket trading. This regulatory showdown highlights growing tensions in the GLP-1 market dominated by Novo Nordisk and Eli Lilly.
4 min read
Hims & Hers $49 Weight-Loss Pill Jolts Industry, Stock Drops
Hims & Hers launched a $49-a-month compounded version of Novo Nordisk's Wegovy, promising affordable GLP-1 weight-loss treatment amid shortages. Yet, despite an initial 14% stock surge, shares closed down 4% as FDA scrutiny loomed. This move highlights tensions in the booming obesity drug market and accessibility challenges for patients.
5 min read